JP2013523776A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013523776A5 JP2013523776A5 JP2013502910A JP2013502910A JP2013523776A5 JP 2013523776 A5 JP2013523776 A5 JP 2013523776A5 JP 2013502910 A JP2013502910 A JP 2013502910A JP 2013502910 A JP2013502910 A JP 2013502910A JP 2013523776 A5 JP2013523776 A5 JP 2013523776A5
- Authority
- JP
- Japan
- Prior art keywords
- growth factor
- nerve growth
- use according
- delivery
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 49
- 102000015336 Nerve Growth Factor Human genes 0.000 claims description 49
- 229940053128 nerve growth factor Drugs 0.000 claims description 49
- 210000003523 substantia nigra Anatomy 0.000 claims description 24
- 210000004556 brain Anatomy 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 210000001577 neostriatum Anatomy 0.000 claims description 14
- 239000013604 expression vector Substances 0.000 claims description 13
- 208000027418 Wounds and injury Diseases 0.000 claims description 11
- 230000006378 damage Effects 0.000 claims description 11
- 230000007547 defect Effects 0.000 claims description 11
- 230000002950 deficient Effects 0.000 claims description 11
- 230000003291 dopaminomimetic effect Effects 0.000 claims description 11
- 208000014674 injury Diseases 0.000 claims description 11
- 210000002569 neuron Anatomy 0.000 claims description 11
- 230000001225 therapeutic effect Effects 0.000 claims description 11
- 208000018737 Parkinson disease Diseases 0.000 claims description 6
- 210000002637 putamen Anatomy 0.000 claims description 6
- 239000013607 AAV vector Substances 0.000 claims description 5
- 230000001668 ameliorated effect Effects 0.000 claims description 5
- CJLHTKGWEUGORV-UHFFFAOYSA-N Artemin Chemical compound C1CC2(C)C(O)CCC(=C)C2(O)C2C1C(C)C(=O)O2 CJLHTKGWEUGORV-UHFFFAOYSA-N 0.000 claims description 4
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 claims description 4
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 claims description 4
- 102100021584 Neurturin Human genes 0.000 claims description 4
- 108010015406 Neurturin Proteins 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 230000003827 upregulation Effects 0.000 claims description 4
- 102100026376 Artemin Human genes 0.000 claims description 2
- 101710205806 Artemin Proteins 0.000 claims description 2
- 241000702421 Dependoparvovirus Species 0.000 claims description 2
- 206010061296 Motor dysfunction Diseases 0.000 claims description 2
- 210000005056 cell body Anatomy 0.000 claims description 2
- 210000005064 dopaminergic neuron Anatomy 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 230000001771 impaired effect Effects 0.000 claims description 2
- 230000007441 retrograde transport Effects 0.000 claims description 2
- 230000000638 stimulation Effects 0.000 claims description 2
- 239000013598 vector Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 206010040925 Skin striae Diseases 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 29
- -1 percefin Proteins 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32065410P | 2010-04-02 | 2010-04-02 | |
| US61/320,654 | 2010-04-02 | ||
| PCT/US2011/031027 WO2011123842A2 (en) | 2010-04-02 | 2011-04-01 | Methods for treating parkinson's disease and other disorders of dopaminergic neurons of the brain |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013523776A JP2013523776A (ja) | 2013-06-17 |
| JP2013523776A5 true JP2013523776A5 (enExample) | 2014-05-15 |
Family
ID=44712866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013502910A Withdrawn JP2013523776A (ja) | 2010-04-02 | 2011-04-01 | パーキンソン病および脳のドーパミン作動性ニューロンのその他の障害を処置する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20120082650A1 (enExample) |
| EP (1) | EP2552473A4 (enExample) |
| JP (1) | JP2013523776A (enExample) |
| CN (1) | CN102821781A (enExample) |
| AU (1) | AU2011235890B2 (enExample) |
| CA (1) | CA2793692A1 (enExample) |
| WO (1) | WO2011123842A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2991301A1 (en) * | 2015-07-13 | 2017-01-19 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
| IL278213B2 (en) | 2018-04-27 | 2026-04-01 | Rocket Pharmaceuticals Ltd | A gene therapy vector encoding an e3 ubiquitin protein ligase (park2) and use thereof in treating or inhibiting the onset of parkinson’s disease (pd) |
| WO2022017630A1 (en) | 2020-07-23 | 2022-01-27 | Ucl Business Ltd | GENE THERAPY VECTOR FOR eEF1A2 AND USES THEREOF |
| AR131771A1 (es) | 2023-02-03 | 2025-04-30 | Janssen Pharmaceutica Nv | Vectores de terapia génica para su uso en la enfermedad de parkinson |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6800281B2 (en) * | 2000-11-09 | 2004-10-05 | Oxford Biomedica (Uk) Limited | Lentiviral-mediated growth factor gene therapy for neurodegenerative diseases |
| CN1897977A (zh) * | 2003-10-20 | 2007-01-17 | Ns基因公司 | 帕金森氏病的体内基因治疗 |
-
2011
- 2011-04-01 CA CA2793692A patent/CA2793692A1/en not_active Abandoned
- 2011-04-01 US US13/078,897 patent/US20120082650A1/en not_active Abandoned
- 2011-04-01 JP JP2013502910A patent/JP2013523776A/ja not_active Withdrawn
- 2011-04-01 CN CN2011800174012A patent/CN102821781A/zh active Pending
- 2011-04-01 AU AU2011235890A patent/AU2011235890B2/en not_active Withdrawn - After Issue
- 2011-04-01 EP EP11763551.6A patent/EP2552473A4/en not_active Ceased
- 2011-04-01 WO PCT/US2011/031027 patent/WO2011123842A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ramaswamy et al. | Trophic factors therapy in Parkinson's disease | |
| JP2019526584A5 (enExample) | ||
| CN104524469A (zh) | 一种跌打药酒 | |
| CN101406586B (zh) | 治疗软组织损伤和肩周炎的外用中药制剂及其制备方法 | |
| CN104474509A (zh) | 一种用于调理眼部屈光的药贴及制备方法 | |
| CN103385945A (zh) | 一种治疗颈椎病的药物 | |
| CN104435281A (zh) | 一种止痒喷剂及其制备方法 | |
| CN101559207A (zh) | 一种治疗颈椎病的中成药 | |
| CN102335391B (zh) | 一种治疗银屑病的熏剂 | |
| CN103893553B (zh) | 一种创面用中药复方膜剂及其制备方法 | |
| CN103623259B (zh) | 一种治疗小儿肺结核的中药外敷剂 | |
| CN103393961B (zh) | 一种治疗颈椎病的中药及其制备方法 | |
| Hassan | Revolutionary Approaches to Managing Neuropathies: A Review of Innovative Therapies | |
| Kwon et al. | Bee venom suppresses methamphetamine-induced conditioned place preference in mice | |
| CN103654042A (zh) | 一种治疗颈椎病的药枕 | |
| Sirui | Research progress on application of phellodendron amurense and coptis chinensis in radiation-induced skin injury. | |
| CN102755437A (zh) | 一种治疗肩周炎的膏药 | |
| CN121371101A (zh) | 一种配合离子导入的外用制剂 | |
| Ju et al. | Pathological changes in the retina and growth associated protein-43 expression following treatment of intracanalicular optic nerve injury via optic canal decompression, dexamethasone or their combination | |
| Salehi et al. | Antidepressant effects of aloe vera hydro alcoholic extract on mice model | |
| 董佳梓 | Effects of electroacupuncture at “Zusanli”(ST 36) on expression of mitophagy-related proteins in skeletal muscle in rats with spleen deficiency syndrome | |
| CN105311138A (zh) | 一种治疗风湿骨病的中药健骨散 | |
| CN105079542A (zh) | 一种防治老年性痴呆的中药提取物及其制备方法 | |
| CN102961509A (zh) | 治疗偏瘫的中药 | |
| CN104435979B (zh) | 一种治疗风湿腰腿疼痛的药物 |